200,000+ products from a single source!
sales@angenechem.com
CAS No: 350992-10-8 Catalog No: AG007FYK MDL No:
Title | Journal |
---|---|
Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT₆ and dopamine D₂ receptor ligands. | Journal of medicinal chemistry 20140710 |
Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats. | Addiction biology 20120301 |
Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. | Psychopharmacology 20120201 |
[Pharmacology of antipsychotics at human dopamine D2 and D3 receptors]. | Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology 20120201 |
In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. | European journal of pharmacology 20111015 |
Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models. | The international journal of neuropsychopharmacology 20111001 |
Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. | Psychopharmacology 20110801 |
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile. | Journal of medicinal chemistry 20110714 |
Newer molecules in the treatment of schizophrenia: A clinical update. | Indian journal of pharmacology 20110401 |
Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. | BMC psychiatry 20110101 |
A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. | PloS one 20110101 |
The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. | The Journal of clinical psychiatry 20101001 |
The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. | Current opinion in investigational drugs (London, England : 2000) 20100701 |
Development and application of an LC-MS/MS method for measuring the effect of (partial) agonists on cAMP accumulation in vitro. | Journal of neuroscience methods 20100430 |
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). | Journal of medicinal chemistry 20100325 |
Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. | Bioorganic & medicinal chemistry 20100301 |
Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. | Current opinion in pharmacology 20100201 |
Tetrabenazine is neuroprotective in Huntington's disease mice. | Molecular neurodegeneration 20100101 |
Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse. | Neuropsychiatric disease and treatment 20100101 |
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys. | Behavioural brain research 20091105 |
Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation. | Neuroscience letters 20090821 |
Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. | European journal of pharmacology 20090401 |
Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. | Journal of psychopharmacology (Oxford, England) 20090301 |
Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole. | Synapse (New York, N.Y.) 20081201 |
Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds. | European journal of pharmacology 20081112 |
Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. | European journal of pharmacology 20081112 |
Serotonergic approaches in the development of novel antipsychotics. | Neuropharmacology 20081101 |
Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. | Psychopharmacology 20081001 |
The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. | European journal of pharmacology 20080911 |
Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to G alpha s. | European journal of pharmacology 20080707 |
Bipolar depression: trial-based insights to guide patient care. | Dialogues in clinical neuroscience 20080601 |
Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells. | The international journal of neuropsychopharmacology 20080501 |
Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice. | Behavioural pharmacology 20080301 |
Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells. | European journal of pharmacology 20080226 |
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. | Molecular psychiatry 20080101 |
Partial agonist actions at dopamine D2L receptors are modified by co-transfection of D3 receptors: potential role of heterodimer formation. | Parkinsonism & related disorders 20080101 |
Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. | Drugs 20080101 |
Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. | European journal of pharmacology 20071128 |
Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties. | Naunyn-Schmiedeberg's archives of pharmacology 20071001 |
Pharmacological causes of hyperprolactinemia. | Therapeutics and clinical risk management 20071001 |
Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation. | Journal of neurochemistry 20070801 |
Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation. | Neuropharmacology 20070801 |
Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. | Psychopharmacology 20070701 |
Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. | Current opinion in investigational drugs (London, England : 2000) 20070701 |
Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors. | Psychopharmacology 20070401 |
Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels. | Neuropharmacology 20070301 |
Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. | Behavioural pharmacology 20070301 |
Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities. | Journal of medicinal chemistry 20070222 |
Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. | Psychopharmacology bulletin 20070101 |
Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20060901 |
In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. | Naunyn-Schmiedeberg's archives of pharmacology 20060901 |
Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. | European journal of pharmacology 20060327 |
Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. | European journal of pharmacology 20060318 |
Aripiprazole: the evidence of its therapeutic impact in schizophrenia. | Core evidence 20060101 |
Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. | The Journal of pharmacology and experimental therapeutics 20051001 |
Molecule of the month. Bifeprunox mesilate. | Drug news & perspectives 20051001 |
Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. | The international journal of neuropsychopharmacology 20050901 |
Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. | Neuropharmacology 20050801 |
DU-127090 Solvay/H Lundbeck. | Current opinion in investigational drugs (London, England : 2000) 20030101 |
New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities. | Bioorganic & medicinal chemistry letters 20010903 |
© 2019 Angene International Limited. All rights Reserved.